Most of colorectal cancer CRC-related death is due to metastasis and the finding of markers for prognosis of invasiveness, constitutes an appealing challenge. Here, after analysing cDNA array containing 43 tumour and 5 normal mucosa samples, we report that the expression of the ZNF518B gene as a whole and that of its two major splicing isoforms are significantly increased in tumours. The canonical isoform was also up-regulated in a patients' cohort containing 70 tumour and 69 adjacent tissue samples. The effects of silencing ZNF518B on the phenotype of CRC cell lines were then studied. The gene does not affect cell proliferation, but plays a significant role in cell migration and invasiveness and induces changes in the epithelial-to-mesenchymal transition markers, suggesting that ZNF518B favours tumour cell dissemination. to study the regulation of the gene, transcription-related changes in nucleosomal organisation and epigenetic marks around the transcriptional start site were analysed. The positioning of a nucleosome over the transcription start site and the differential presence of the epigenetic marks H3K9ac, H3K27ac, H3K4me3 and H3K9me3 correlate with gene expression.
protein. No evidence for the actual existence of this truncated protein exists. The three remaining isoforms are non-protein coding.
Apart from the data mentioned above, there are only a few reports in the literature concerning the role of ZNF518B. It is clear from sequence data that isoform 1 encodes a zinc-finger protein, a putative transcriptional factor for which the identification of its possible targets remains to be determined. Single nucleotide polymorphisms have been described to occur at or close the ZNF518B gene in association with gout and/or serum urate concentration [4] [5] [6] . More interestingly to our purpose, in a proteomic analysis of the interactome of G9A, Maier et al. found that ZNF518B is one of the partners of the histone methyltransferase. The whole in vitro translated ZNF518B protein, as well as its deletion fragments, are able to interact with G9A, showing that multiple domains are involved in the interaction. ZNF518B positively regulates the methylation of H3K9, suggesting that its binding to G9A result in the activation of the enzyme 7 .
These facts establish a potential relationship between ZNF518B and cancer, because a dysregulation of G9A has been found in several types of cancer 8 . Specifically, the enzyme is overexpressed in CRC tissues when compared to paired normal epithelium and its down-regulation inhibits proliferation of cancer cells 9 . In view of the above data, it seems clear that an overexpression of ZNF518B may have deleterious effects on cancer progression and invasiveness. However, to date no reports on the differential expression of ZNF518B between cancerous and normal tissues have appeared. Should the gene be overexpressed in cancer tissues, it might be added to the available panel of molecular markers. In the present research, we first analysed the level of ZNF518B in 45 CRC patient-derived cDNA samples, to find that there is a significantly higher expression in these samples than in normal mucosa. Isoform 1 is also up-regulated in a larger patients' cohort. In view of these results, we further describe in this paper that ZNF518B is involved in migration and invasiveness of CRC cell lines, and that the regulation of gene expression takes place at a chromatin level.
Results
ZNF518B is overexpressed in human CRC. The ZNF518B expression analysis in human CRC patients was first carried out with a TissueScan cDNA array (OriGene). The array used contained 5 cDNA samples from normal mucosa; the analysis of the original tissues, provided by the supplier, showed normal histological appearance. The array also contained 43 cDNA samples from CRC patients, 10 from stage I, 13 from stage II, 14 from stage III and 6 from stage IV. They corresponded to 21 males and 27 females, with an age range from 36 to 92 years and an average of 68.5 ± 13.3 years. The expression of the ZNF518B gene as a whole and of its isoforms 1 and 2 was determined by RT-qPCR in all the samples. Both the whole gene and its isoforms are significantly overexpressed in human CRC at all stages but no significant differences were observed from one stage to another ( Fig. 1) . Then, the expression of the gene was analysed in a prospective study with a cohort of 101 patients, who underwent surgery at the University Hospital (Valencia) in the last 3 years ( Supplementary Table S1 ). The quality of the cDNA prepared by retrotranscription of RNA isolated from paraffin-embedded samples, together with the low expression level of the gene, did not allow us to amplify all the samples by RT-qPCR. Therefore, only the results obtained with the canonical isoform from non-paired 70 tumour and 69 non-tumour adjacent samples are presented in Fig. 2 , which shows that, in agreement with the data obtained from the cDNA array, ZNF518B is significantly up-regulated in human CRC.
Once determined that the expression of the gene is enhanced in CRC tissues, the mechanisms putatively involved in the ZNF518B-related malignancy development, as well as those governing the regulation of the gene expression, were studied in vitro with CRC-derived cell lines. The results are described in the next sections.
Effects of ZNF518B on the proliferation of CRC cells.
To explore the function of ZNF518B in human CRC progression, the effects of the gene on cell growth were first analysed. To do this, the gene was silenced with ZNF518B siRNA. After checking the effects of several commercial siRNAs on the knocking-down of both major isoforms of the gene, the equimolar mixture of the two siRNAs described under Materials and Methods was further used. One of the siRNAs silenced both isoforms 1 and 2, while the other targets only at isoform 1 ( Supplementary Fig. S1a ).
To achieve a most effective knocking down, in most of the following experiments we used an equimolar mixture of both siRNAs. As shown in Fig. 3a , the mixed siRNAs are more efficient in knocking-down the expression of isoform 1 (to 18% in DLD1 and to 12% in HCT116 cells) than that of isoform 2 (to 62% in DLD1 and to 34% in HCT116) 48 h after transfection. These trends are maintained after 96 h ( Supplementary Fig. S2 ). The consequences of the knocking-down were evaluated by both, MTT and colony formation assays. MTT assay showed that ZNF518B does not appreciably influence proliferation of DLD1, while a decrease in the expression of the gene causes a small, but significant, reduction in the proliferation of HCT116 cells (Fig. 3b ). Cell cycle analysis revealed no significant differences in any of the cell lines after ZNF518B knocking-down ( Supplementary Fig. S3 ). Results of Fig. 3c,d show that ZNF518B does not appreciably influence the colony-forming capacity of DLD1 and HCT116 cells.
Involvement of ZNF518B in epithelial-to-mesenchymal transition. The effects of silencing
ZNF518B (see above) on cell migration were studied with DLD1 and HCT116 cell lines by transwell and wound healing assays. The results of the transwell analysis ( Fig. 4a,b) show that ZNF518B knocking-down significantly reduces cell migration and the wound healing assay ( Fig. 4c ) confirmed these results. The migration assays were also done with the individual siRNAs and in both cases a significant reduction of cell migration after knocking down the gene was observed ( Supplementary Fig. S4 ). These results show that the two siRNAs do not have off-target effects. When the transwell analysis was carried out through a Matrigel layer to explore the effects of the gene on invasiveness, it was observed that silencing of the gene significantly reduces the invasion of cells through extracellular matrix ( Fig. 4d,e ). Finally, the adhesion of cells to type I collagen fibres was also influenced www.nature.com/scientificreports www.nature.com/scientificreports/ by silencing ZNF518B (Fig. 4f ). All of the above events are usually associated with epithelial-to-mesenchymal transition (EMT). Therefore, the effects of ZNF518B expression on the level of EMT markers were next examined. Figure 5a shows that knocking-down ZNF518B in DLD1 cells resulted in a significant decrease in the expression of SNAI1gene after treating the cells with siRNA for 48 h. SNAIL, the product of this gene, is a transcriptional repressor of the E-cadherin gene and, accordingly, CHD1 transcription is significantly increased in DLD1 cells after knocking-down the ZNF518B gene ( Fig. 5b ). The levels of the proteins encoded by these genes were determined after 72 h of treatment with siRNA, taking into account the lag time existing between transcription and steady state accumulation of protein. SNAIL was drastically reduced by silencing ZNF518B (Fig. 5c,d ). The level of E-cadherin protein was so low that we could not detect it. This was not the case with N-cadherin which decreases after silencing. The observed decrease in the levels of SNAIL and N-cadherin parallels that of ZNF518B protein ( Fig. 5c,d ). From these experiments it can be concluded that ZNF518B promotes migration and invasiveness of CRC cells. Therefore, the gene might be considered as involved in EMT and cancer cell dissemination, probably through type I collagen fibres.
Factors influencing ZNF518B expression. In view of the above results, it is interesting to explore the molecular causes involved in the regulation of ZNF518B expression. This may be adequately done through a comparison of the behaviour of SW48 and DLD1, because the gene is not transcribed in the former cell line, while it is in the second one.
As nucleosome organisation may play a regulatory role in gene expression, the chromatin structure at the promoter and proximal transcribed region was first studied. The results of a micrococcal nuclease protection assay from −1,000 to +300 relative to the transcription start site (TSS) are given in Fig. 6a , which also includes the location of the tiled amplicons used (see Supplementary Table S2 ). The protection profile of the D-Mut1 cell line, in which the ZNF518B gene is also expressed 3 , was included as a control. This assay offers a convenient method to analyse nucleosome positioning 10, 11 . Most of the peaks can be ascribed to the presence of nucleosomes as their width is compatible with nucleosomal size. A model for the nucleosomal organisation of the region under study is depicted in Fig. 6b . The nuclease-protected region between −500 and −800 may be ascribed either to two nucleosomes closely packed together or to a single nucleosome, N − 3, which may occupy a series of sites due to sequence-directed, rotational positioning determinants. At any rate, as this aspect of chromatin structure is When examining the entire region analysed ( Fig. 6a ) it can be observed that the chromatin organisation in the three cell lines is very similar save in two details. First, the overall protection to micrococcal nuclease is higher in the SW48 cell line, in which ZNF518B is not expressed. Second, there is a clear difference in the chromatin structure of the cell lines around the TSS. While in DLD1 and D-Mut1 cells the location of five nucleosomes (N + 1 and N − 4 to N − 1) may be postulated and the TSS encompasses a nucleosome-free region, in SW48 cells the TSS is protected, suggesting that an additional nucleosome is positioned over it. This region is observed in more detail in Fig. 6c . The sequence-based analysis of nucleosome positioning recovered from the NuPop programme ( Fig. 6d ) predicts the presence of a nucleosome between −100 and +45. In spite of the high probability predicted, the DLD1 and D-Mut1 cells lack a nucleosome over TSS, while the nuclease protection assay suggested that a nucleosome actually is located in that position in SW48 cells. It seems obvious that the chromatin structure accounted, at least in part, for the differences in gene expression between these cell lines.
Epigenetic modification of histones is commonly associated with transcriptional regulation. Therefore, the presence of some epigenetic marks in the three cell lines was next studied. The determination was carried out by Nuc-ChIP, which allows the localisation of histone modifications at single nucleosome level 11 . Acetylation at H3K9 and H3K27, associated with transcriptional activity 12, 13 , is characteristic of promoter nucleosomes 10 . H3K4me3 and H3K9me3, which are usually associated, respectively, with active and repressed chromatin [12] [13] [14] [15] , are preferentially found in the proximal transcribed region 10 . Therefore, Nuc-ChIP to quantify H3K9ac and H3K27ac was done at amplicons −521, −324 and −108, which cover, respectively, nucleosomes N − 3, N − 2 and N − 1; H3K4me3 and H3K9me3 were analysed at amplicon +75, which cover the first part of nucleosome N + 1 in DLD1 and D-Mut1 cells and the second part of the nucleosome occupying the TSS in SW48. Figure 7A shows that nucleosomes N − 3, N − 2 and N − 1 are enriched in H3K9ac and H3K27ac in DLD1 and D-Mut1 cells, while the marks are less abundant in SW48 cells. H3K4me3 is more abundant in nucleosome N + 1 from the cells in which the gene is transcribed. On the contrary the mark H3K9me3 is especially present in the nucleosome covering the TSS in SW48 cells (Fig. 7B ).
To check that histone acetylation is actually involved in the regulation of ZNF518B transcription, we treated SW48 cells, in which the gene is not appreciably expressed, with trichostatin A (TSA), an inhibitor of histone deacetylases. The treated cells showed an enhancement in H3 acetylation ( Supplementary Fig. S5 ), a significant time-dependent increase in ZNF518B expression ( Fig. 8a) and a greater migration rate (Fig. 8b,c) , a result compatible with the TSA-induced changes in ZNF518B expression. The experiments described under the present heading are compatible with the idea that the organisation of chromatin and its epigenetic marks are important factors in the regulation of ZNF518B transcription in the CRC cell lines studied. www.nature.com/scientificreports www.nature.com/scientificreports/
Discussion
The results described here, obtained from both a cDNA array of 43 tumour and 5 normal mucosa samples and from a local prospective cohort including 70 tumour and 69 adjacent non-tumour samples, show for the first time that the expression of ZNF518B may correlate with CRC. We have previously reported that the expression of ZNF518B isoforms 1 and 2 is roughly equivalent in HCT116, DLD1, D-Mut1 and DWT7m CRC cell lines 3 and present results show that the levels of both isoforms are similar in CRC patients. In this paper we show that isoform 1 is up-regulated in a large cohort of patients and the analysis of isoform 2 is now being studied in our group. This issue may prove to be interesting, because isoform 2 mRNA is putatively translated to give a truncated product, consisting of the 75 N-terminal amino acids. Should this polypeptide actually occur, it may compete with the whole protein derived from isoform 1 mRNA in its interaction with G9A, because these truncated polypeptides from the N-terminus of the protein are still able to bind the histone methyltransferase 7 . Both ZNF518B isoforms might then play a functional role; isoform 1 as a zinc-finger containing transcriptional factor interacting with G9A, and isoform 2, devoid of the zinc-finger domains, competing with isoform 1. Interaction of isoform 1 with G9A results in the activation of the enzyme 7 , which is involved in invasiveness and metastasis in several cancer types 16, 17 . We do not know whether isoform 2 would compete with isoform 1 in the binding to G9A. If it were, changes in the ratio of isoforms would represent an additional way to regulate the activity of the methyltransferase. www.nature.com/scientificreports www.nature.com/scientificreports/ Present knocking-down experiments with ZNF518B siRNA showed that the expression of the gene does not influence cell growth. Nevertheless, the gene is clearly involved in cell migration and invasiveness, probably through type I collagen fibres. These fibres play a crucial role in cancer progression (for a review, see 18 ), and they have been described as the "highways" for tumour cell migration 19 . It remains to be determined whether the effects of ZNF518B in invasiveness are mediated by the activation of G9A. It has been reported that G9A represses the expression of E-cadherin 17 and the results of Fig. 5 show that the down-regulation of ZNF518B results in a significant increase of CDH1 expression. Therefore, the suggestion can be made that the effects of ZNF518B on cell migration are related to the activation of the G9A methyltransferase.
The dysregulation of signalling pathways in cancer has been widely studied, as it often causes changes in gene expression that ultimately result in the development of malignancies. However, less attention has been paid to the involvement of chromatin structure and modifications in the regulation of particular genes involved in www.nature.com/scientificreports www.nature.com/scientificreports/ cancer. The importance of this issue cannot be disregarded, because the regulation of eukaryotic gene expression has to be considered within the landscape of chromatin. In this sense, the value of the experiments described here is reinforced, as they strongly suggest that the expression of ZNF518B is regulated by chromatin structure and epigenetic factors. The presence of a sequence-directed, positioned nucleosome covering the TSS in SW48 cells precludes the assembly of the pre-initiation complex resulting in transcriptional repression. On the contrary, a nucleosome-free region exists in ZNF518B-expressing cells around the TSS. Probably, the action of a chromatin-remodelling complex is responsible for these changes in chromatin structure and alterations in these remodelling machines have been described in many types of cancer 20 . Moreover, mutations in the ATPase subunit of SWI/SNF complex have been considered as drivers of cancer 21 .
Apart from chromatin organisation, epigenetic modification of histones is also involved in the regulation of ZNF518B expression. The nucleosomes N − 3, N − 2 and N − 1 of DLD1 and D-Mut1 cells, in which the gene is transcribed, are enriched in H3K9ac and H3K27ac, a signature of promoter nucleosomes in active genes 10 , whereas the level of these marks is significantly lower in SW48 cells. Our results prove that enhancing the level of H3 acetylation by TSA treatment results in a noticeable transcription of ZNF518B in SW48 cells, which, otherwise, express the gene to a negligible level. The methylation marks at N + 1 nucleosome are also compatible with their role in the regulation of gene expression. When these circumstances are considered together with the assumption that ZNF518B is involved in EMT, which, in turn, has been associated to modifications in the histone epigenetic marks 22 , the ZNF518B gene might be added to the list of epigenetic targets for cancer therapy. As TSA affects the expression of multiple genes in cancer cells 23 , a causal relationship between TSA treatment and increased migration of SW48 cells cannot be established from the experiments shown in Fig. 8 . Anyway, it is clear that histone acetylation is implicated in the regulation of ZNF518B expression, which, in turn, is involved in cell migration and other pathogenic effects. Fortunately, several therapeutic approaches are being developed in this sense 20, 24 and it would be worth exploring these possibilities in the case of ZNF518B gene. Further work, based on larger patients' cohorts, may decide its actual clinical value as a candidate for invasiveness prognosis in CRC, as well as its potentiality as a target for epigenetic drugs.
Methods
Human CRC samples. ZNF518B expression was first analysed inTissueScan CRC cDNA arrays (OriGene, HCRT101, Rockville, USA). Clinical samples were obtained from the INCLIVA biobank. 101 paraffin-embedded CRC paired samples from stages I-IV patients were used; their clinicopathological characteristics are given in Supplementary Table S1 . Written informed consents were obtained from all the patients before surgery and all the procedures were carried out in accordance with the Declaration of Helsinki and other relevant guidelines. The study was approved by the Ethical Committee of the Hospital Clínico from the University of Valencia (Comité Ético de Investigación Clínica del Hospital Clinic Universitari de València, No. 2017/229). www.nature.com/scientificreports www.nature.com/scientificreports/ Cell culture. The human CRC cell lines SW48 (Horizon), HCT116 (ATCC CCL-247), DLD1 (ATCC CCL-221) and its isogenic derivative D-Mut1 (a gift from Dr B. Vogelstein), were grown as previously described 3 . To guarantee the continued quality of the cell lines used in this study, a short tandem repeat DNA profiling of the cells was performed. Genomic DNA was extracted at different steps of the study and Bioidentity (Elche, Spain), a biotechnology company of genetic analysis, monitored the identity of the cells. The analyses confirmed the identity of the cell lines, complying with international standards of authentication (ANSI/ATCC).
To inhibit histone deacetylases, cells were loaded in 6-well plates and treated with 0.25 μM TSA (Sigma). Controls were treated with the dimethylsulphoxide-containing solvent. ZNF518B knockdown. DLD1 and HCT116 cells were cultured in 6 well plates to 50-60% confluence and transfected with 20 nM of either scrambled siRNA (Qiagen 1027280), ZNF518B siRNAs (Qiagen SI04131015) or (Qiagen SI04284805). Lipofectamine RNAi Max (#1875252 Invitrogen) was used according to the instructions of the manufacturer. The cells were then incubated in CO 2 atmosphere for several times at 37 °C. The efficiency of knockdown was checked by RT-qPCR and western blotting.
Cell proliferation assay. Cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After 24 h of transfecting the cells with scrambled siRNA, or with the ZNF518B siRNAs, 3,000 cells per well were seeded in quadruplicate in 96-well plates and 10 μl of a 5 mg/ml solution of MTT in phosphate buffered saline (PBS) were added to each well containing 100 μl of culture medium at several times after seeding. The spectrophotometric determination of proliferation was done following the recommendations of the manufacturer. www.nature.com/scientificreports www.nature.com/scientificreports/ Cell migration and invasion assays. Cell migration and invasion assays were carried out in 12 well plates (Corning, Falcon, Cell Culture Inserts, with 8 μm pore size). For invasion assays, 50 μl matrigel (BME 2 RGF PathClear, Sigma-Aldrich) were loaded in the upper chamber prior to the introduction of the cells. For both 
